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The primary aim of this study was to examine prospectively the associations between 5 peroxisome proliferator-activated recep-
tor (PPAR) single nucleotide polymorphisms (SNPs) and cardiovascular morbidity and mortality in a community-based cohort
study in Washington County, Maryland. Data were analyzed from 9364 Caucasian men and women participating in CLUE-II.
Genotyping on 5 PPAR polymorphisms was conducted using peripheral DNA samples collected in 1989. The followup period was
from 1989 to 2003. The results showed that there were no statistically signiﬁcant associations between the PPAR SNPs and cardio-
vascular deaths or events. In contrast, statistically signiﬁcant age-adjusted associations were observed for PPARG rs4684847 with
both baseline body mass and blood pressure, and for PPARG rs709158, PPARG rs1175543, and PPARD rs2016520 with baseline
cholesterol levels. Future studies should be conducted to conﬁrm these ﬁndings and to explore the associations in populations
with greater racial and ethnic diversity.
Copyright © 2008 L. Gallicchio et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The peroxisome proliferator-activated receptors (PPARs) are
part of a superfamily of ligand-activated transcription fac-
tors involved in fatty acid oxidation and lipid metabolism
[1]. Three distinct isoforms of PPARs that are encoded by
separate genes have been identiﬁed: PPAR-α, PPAR-γ,a n d
PPAR-δ [2]. The three isoforms play distinct physiologi-
cal roles depending on their tissue distribution. PPAR-α,
which is expressed in the liver, heart, skeletal muscle, and
kidney, regulates lipid and lipoprotein metabolism. PPAR-
γ is expressed in white and brown adipose tissue and is in-
volved in adipocyte diﬀerentiation, lipid storage, and glucose
metabolism. PPAR-δ is expressed in many tissues and stim-
ulates fatty acid oxidation [2, 3]. Beyond these major roles,
PPARs also have been shown to play a role in other biologi-
cal processes, including the regulation of inﬂammatory and
oxidative pathways [2].
PPARs are found in endothelial and vascular smooth
muscle cells and have been shown to inﬂuence inﬂamma-
tory, ﬁbrotic, and hypertrophic responses in the heart and
vascular wall [4]. Because of their location and their involve-
ment in fatty acid oxidation, lipid metabolism, and inﬂam-
mation, the role of PPARs in cardiovascular disease and risk
factors of cardiovascular disease has been of great interest.
In general, activation of the PPARs, both naturally and syn-
thetically, is considered beneﬁcial for cardiovascular health
[2]. Both PPAR-α and PPAR-γ play a role in modulating2 PPAR Research
atherosclerosis; for example, PPAR-γ activation may pro-
mote monocyte apoptosis, contributing to the stabilization
of atherosclerotic lesions [5, 6]. Further, clinical trials have
shownthattheuseofpharmacologicalPPARagonistssuchas
ﬁbrates (PPAR-α agonist) is antiatherogenic. Fibrates elevate
high-density lipoprotein (HDL) levels, decrease low-density
lipoprotein (LDL) and triglyceride levels, and reduce an in-
dividual’s risk of experiencing a cardiac event [7].
An u m b e ro fPPAR polymorphisms have been identi-
ﬁed within the 3 PPAR isoforms and there is a consider-
able amount of literature on the associations between these
polymorphisms and cardiovascular risk factors (reviewed in
Cresci [7]). There are less data, however, on the associations
between the PPAR polymorphisms and cardiovascular dis-
ease events (e.g., myocardial infarction (MI), cardiovascular-
related death). Further, ﬁndings with regard to these asso-
ciations have been inconsistent. For example, a case-control
study nested within the Physician’s Health Study suggested
that the PPARG Pro12Ala polymorphism, located in exon B
of PPAR-γ, is associated with a reduced risk of MI [8]. In
contrast, a recent publication using data from the Health
Professionals Followup Study showed that male carriers of
the Ala12 allele had an increased risk of MI or cardiac death
[9] while other studies have observed no statistically signiﬁ-
cant association between PPARG Pro12Ala and cardiovascu-
lar events or death [9, 10]. Thus, additional studies of these
polymorphisms are necessary to help us better understand
the role of PPAR genetics in cardiovascular disease especially
in light of available pharmacological PPAR targeted agents.
The primary aim of this study was to examine prospec-
tively the associations between 5 PPAR polymorphisms (4
in PPAR-γ: rs4684847, rs709158, rs1175543, and rs1801282;
and 1 in PPAR-δ: rs2016520) and cardiovascular morbidity
and mortality in a community-based cohort study in Wash-
ingtonCounty,Maryland.Asasecondaryaim,wealsoexam-




In 1974 and 1989, two cohorts named CLUE I and CLUE II
(“Give us a Clue to Cancer and Heart Disease”) were estab-
lished in Washington County, Maryland. CLUE I and CLUE
II enrolled 20305 and 25081 Washington County residents,
respectively. At baseline for both cohorts, participants pro-
vided informed consent, completed a brief questionnaire,
and donated a blood sample. The questionnaire ascertained
data on age, gender, marital status, education, height and
weight (CLUE II only), cigarette smoking, and medication
and vitamin supplement use within the 48 hours prior to
blood donation. In addition, in both 1974 and 1989, blood
pressure was measured by a study nurse with a blood pres-
surecuﬀwhiletheparticipantwasinaseatedposition.Blood
pressure was assessed three times in succession and the third
blood pressure value was recorded. In 1989, total cholesterol
(nonfasting) was assayed. Individuals who donated blood to
both CLUE I and CLUE II constitute the Odyssey cohort (N
= 8394) [11, 12].
In addition to the Odyssey cohort, a CLUE II subcohort
was selected for case-cohort studies that would be conducted
using the CLUE II cohort data. The subcohort was identiﬁed
by taking an approximate 10% age- and sex-stratiﬁed ran-
dom sample of CLUE II participants who donated a blood
specimen and were adult residents of Washington County,
Maryland. Of the 2460 participants identiﬁed for the subco-
hort, 807 were also in the Odyssey cohort. Therefore, 10047
uniqueparticipantswerepartofeithertheOdysseycohortor
the randomly selected CLUE II subcohort.
Of the participants in the Odyssey Cohort and the CLUE
II subcohort, DNA was successfully extracted from the buﬀy
coat samples of 9960 individuals (99.1%). DNA from these
participantswasgenotypedforpolymorphismsingenescon-
trolling biological processes such as inﬂammation that have
been associated with multiple diseases. For the study pre-
sented here, 5% of the Odyssey and subcohort participants
who had no data on all of the chosen PPAR SNPs (n = 475)
were excluded from the analysis. Further, all non-Caucasians
(n = 121) were excluded from the analysis because previous





with respect to baseline characteristics. This study was ap-
proved by the Institutional Review Board of the Johns Hop-
kins Bloomberg School of Public Health.
2.2. Outcomeassessment
Mortality
All participants were followed from the date of blood draw
to the date of death or the end of follow up (August 31,
2003), whichever came ﬁrst. In the CLUE cohorts, deaths are
identiﬁed through daily searches of obituaries, cross-linkage
with death certiﬁcates for Washington County, and through
searches of the Social Security Administration for individu-
als aged 65 or older and the National Death Index. Cause of
death is ascertained from the underlying cause on Maryland
State death certiﬁcates as coded by state nosologists. Of spe-
ciﬁc interest in this study were cardiovascular disease deaths,
for which the underlying cause was coded as ICD-9 390–459
or ICD-10 I00–I99. During the followup period, 2159 deaths
were documented in the Odyssey cohort and the CLUE II
subcohort, and of these, 791 (36.6%) were cardiovascular
deaths. Approximately 4% (n = 334) of the Odyssey cohort
and the CLUE II subcohort participants were lost to follow
up.Sincetheseindividualswerenotdocumentedtohavedied
during the followup period, they were considered alive at the
end of follow up and censored at August 31, 2003.
Morbidity
Information on cardiovascular events was obtained us-
ing participant self-report beginning with questionnairesL. Gallicchio et al. 3
administered in 1996 and about every 2 years thereafter.
On these questionnaires, participants were asked whether
a “doctor had told them they ever had” a speciﬁc condi-
tion and at what age the condition was ﬁrst diagnosed. The
cardiovascular-relatedoutcomesqueriedwere:diabetes,high
blood pressure, high cholesterol, heart attack (MI), angina
pectoris, stroke, transient ischemic attack, peripheral artery
disease, arrhythmia, and blood clots. Data were examined
across the questionnaires for consistency; 5% of the partic-
ipants had inconsistent data with regards to self-reported
events. However, exclusion of these participants did not
change the results and, therefore, these participants were not
excluded. For this analysis, we examined any self-reported
nonfatal cardiovascular event as an outcome. A nonfatal car-
diovascular event was deﬁned as consistent reporting from
1996 to 2003 of any one of the following cardiovascular con-
ditions:MI,angina,stroke,transientischemicattack,periph-
eral arterial disease, arrhythmia, or blood clots. We also con-
sidered a composite variable including only MI, stroke, tran-
sient ischemic attack, and peripheral arterial disease; how-
ever, the results were similar to the composite variable in-
cludingallsevenoutcomesand,therefore,thesevenoutcome
variable was used in all analyses. Individual diagnoses were
also examined separately. Because of the inconsistency in the
collectionofdataontheageatwhichaconditionoccurredas
well as the large amount of missing data for the age variables,
age at diagnosis data were not used in the analysis.
2.3. Genotyping
The PPAR SNPs analyzed in this study were a part of a
larger group of 210 SNPs selected for investigation within
the Odyssey cohort. SNPs were selected based on the fol-
lowing criteria: (a) the minor allele frequency was estimated
to be ≥5% among Caucasians in the published literature or
databases; (b) the polymorphism was in a gene of known or
of promising importance in the development of cancer, car-
diovascular diseases, and/or longevity; and (c) the polymor-
phismwaseitherknowntobefunctionalorwaslikelytoalter
function based on the published literature. PPAR polymor-
phisms selected for analysis were rs2016520 (PPARD Ex4 +
15C > T), rs709158 (PPARG IVS9 + 4523A > G), rs1175543
(PPARG IVS9 + 7780A > G), rs1801282 (PPARG Pro12Ala),
and rs4684847 (PPARG IVS3-6622C > T). To note, none of
the other 210 SNPs selected for investigation in the Odyssey
cohort were located in PPAR-α,P P A R - γ,o rP P A R - δ.
DNA extracted from the preserved buﬀyc o a ts a m p l e s
collected in 1989 were used for genotyping. Within 6 hours
of collection, the heparinized blood sample was centrifuged
at 1500g for 30 minutes at room temperature. Blood sam-
ples were separated into plasma, buﬀy coat, and red blood
cells and frozen at −70oC within 24 hours of collection. The
buﬀy coat remained frozen until DNA extraction was per-
formed. The DNA extraction procedures used the alkaline
lysis method [13]. Genotyping was performed by Celera Ge-
nomics Co. (Rockville, Md, USA) for rs4684847, rs709158,
and rs1175543 and by Applied Biosystems Inc. (Foster City,
Calif, USA) for rs2016520 and rs1801282. All polymor-
phisms were genotyped using TaqMan technology. Labora-
tory technicians were masked to disease status. Of the 9,364
participants in the analytic cohort, approximately 90% had
data on all ﬁve genotypes; 6.7% had data on four, 2.4% had




a goodness-of-ﬁt approach. As reported in separate publica-
tion, all of the PPAR SNPs were in Hardy-Weinberg equilib-
rium [12]. The cohort characteristics were stratiﬁed by gen-
der and compared using chi-square tests or student t-tests.
Blood pressure at baseline was categorized into 3 groups
independent of antihypertensive medication use as follows:
normal, individuals with a systolic pressure less than 120 and
diastolic pressure less than 80; hypertensive, those with sys-
tolic pressure greater than 140 or diastolic pressure greater
than 90; and prehypertensive, those with a systolic pressure
between120and140ordiastolicpressurebetween80and90.
The age-adjusted associations between the PPAR SNPs and
cardiovascularriskfactors(i.e.,baselineBMI,cholesterollev-
els, blood pressure) were examined using logistic regression
models. Age was adjusted for in all analyses as there were sta-
tistically signiﬁcant age diﬀerences for several of the SNPs.
Gender was not adjusted for in these analyses because it was
not associated with SNP prevalence. Cox-proportional haz-
ard ratios were calculated for both all-cause and cardiovas-
cular mortality after adjustment for age. Since the nonfatal
cardiovascular outcomes (including MI), followed a Poisson
distribution, and age at diagnosis data were not used in the
analysis, age-adjusted relative risks for nonfatal cardiovascu-
lar events and for only MI were obtained using Poisson re-
gression methods; this type of analysis was also used when
analyzing fatal and nonfatal outcomes combined. Premature
death (both overall and due to cardiovascular disease) was
also examined as an outcome variable and deﬁned as death
prior to the age of 65. All analyses were done separately for
the 5 SNPs and stratiﬁed by gender, diabetes diagnosis, and
body mass index (BMI) at baseline. No diﬀerences in the risk
estimates were observed in these strata and, therefore, only
results for the entire cohort are presented.
To address the issue of multiple testing in this study, P
values for the associations between SNPs and the cardiovas-
cular risk factors were adjusted for the false discovery rate
utilizing Fisher’s combination method using bootstrap re-
sampling. All statistical analysis was carried out using SAS
software, version 9.1 (SAS Institute, Inc., Cary, NC, USA).
A two-sided P value ≤.05 was considered statistically signiﬁ-
cant.
3. RESULTS
Baseline characteristics of the study sample, overall and by
gender, are shown on Table 1. In 1989, males were signiﬁ-
cantly more likely than females to have some college educa-
tion, to report being a current or former smoker, and to be
categorized as prehypertensive or hypertensive. In addition,
males had a signiﬁcantly higher mean BMI than females. In4 PPAR Research
Table 1: Characteristics of study sample by gender, N = 9364, P value derived from χ2 test for categorical variables, Student’s t-test for
continuous variables.
Female N = 5776 (%) Male N = 3588 (%) Total (%) P value
Age, mean(SD) 53.2 (15.4) 52.9 (15.5) 53.1 (15.4) .3974
Education .0029
<12 24.5 25.0 24.7
12 47.3 44.0 46.0
>12 28.2 31.0 29.3
Missing, n 41 5
BMI, kg/m2, mean (SD) 26.1 (5.3) 26.6 (4.0) 26.3 (4.9) <.0001
BMI, kg/m2 <.0001
<25 48.8 34.0 43.1
25–30 30.8 48.8 37.7
>30 20.4 17.3 19.2
Missing, n 11 1 12
Smoking status <.0001
Never 62.5 40.3 54.0
Former 21.4 42.7 29.6
Current 16.1 17.0 16.4
Missing, n 0
Cholesterol no Rx, mg/dL <.0001
≤200 41.3 48.2 43.9
200–239 37.1 36.9 37.0
≥240 21.6 14.9 19.1
Cholesterol with Rx, mg/dL <.0001
≤200 15.7 36.0 23.1
200–239 43.9 36.5 41.2
≥240 40.4 27.5 35.7
Blood pressure <.0001
Normal 30.2 15.6 24.6
Prehypertensive 56.4 67.6 60.7
Hypertensive 13.4 16.8 14.7
Missing, n 56 1 1
PPARG rs4684847 .0910
CC 78.8 77.3 78.2
CT/TT 21.2 22.7 21.8
Missing, n 188 120 308
PPARG rs709158 .4741
AA 39.6 40.3 39.8
AG/GG 60.4 59.7 60.2
Missing, n 134 98 232
PPARG rs1175543 .9218
AA 40.2 40.1 40.2
AG/GG 59.8 59.9 59.8
Missing, n 136 91 227
PPARD rs2016520 .5240
CC 64.6 64.0 64.4
CT/TT 35.4 36.0 35.6
Missing, n 146 104 250
PPARG rs1801282 .2728
Pro/Pro 78.4 77.5 78.1
Pro/Ala or Ala/Ala 21.6 22.5 21.9
Missing, n 156 106 262L. Gallicchio et al. 5
Table 2: The associations between PPAR SNPs and cardiovascular risk factors. Goodness of ﬁt likelihood ratio P value using logistic re-
gression modeling adjusted for age; P v a l u ef o ra g eb a s e do nS t u d e n t ’ st-test. Combined outcomes had condition at baseline or reported on
followup questionnaires (for diabetes, self-reported on followup questionnaires only).
(a)
Risk factors PPARG rs4684847 PPARG rs709158 PPARG 1175543
CC CT/ TT P value AA AG/GG P value AA AG/GG P value
Baseline characteristics
Age, mean(SD) 53.0 (15.5) 53.4 (15.4) .3571 52.7 (15.4) 53.3 (15.4) .0780 52.9 (15.5) 53.3 (15.3) .1910
BMI, kg/m2, n (%) .0203 .8458 .9777
<25 3097 (79) 815 (21) 1562 (40) 2372 (60) 1575 (40) 2366 (60)
25–30 2645 (78) 745 (22) 1392 (40) 2048 (60) 1393 (41) 2037 (59)
>30 1331 (76) 412 (24) 681 (39) 1067 (61) 696 (40) 1059 (60)
Cholesterol no Rx, mg/dL, .7144 .0370 .0198
n (%)
≤200 2956 (79) 791 (21) 1469 (39) 2295 (61) 1481 (39) 2284 (61)
200–239 2443 (78) 702 (22) 1274 (40) 1897 (60) 1281 (40) 1904 (60)
≥240 1275 (79) 346 (21) 674 (41) 964 (59) 688 (42) 943 (58)
Cholesterol with Rx, mg/dL, .8997 .4595 .3418
n (%)
≤200 82 (76) 26 (24) 40 (36) 71 (64) 37 (34) 71 (66)
200–239 141 (74) 50 (26) 78 (39) 121 (61) 79 (40) 119 (60)
≥240 125 (75) 42 (25) 70 (41) 102 (59) 70 (41) 102 (59)
Blood pressure, n (%) .0248 .0513 .0509
Normal 1777 (79) 460 (21) 875 (39) 1369 (61) 882 (39) 1362 (61)
Prehypertensive 4290 (78) 1193 (22) 2209 (40) 3338 (60) 2221 (40) 3322 (60)
Hypertensive 1005 (76) 320 (24) 549 (41) 782 (59) 561 (42) 779 (58)
Combined outcomes
Diabetes, n (%) .7845 .8617 .5499
No 4504 (78) 1243 (22) 2325 (40) 3466 (60) 2350 (41) 3451 (59)
Yes 821 (78) 225 (22) 420 (40) 643 (60) 418 (39) 648 (61)
High cholesterol, n (%) .3452 .4527 .5670
No 2502 (78) 706 (22) 1280 (40) 1944 (60) 1296 (40) 1938 (60)
Yes 2712 (79) 730 (21) 1408 (40) 2081 (60) 1414 (41) 2075 (59)
High blood pressure, n (%) .6258 .2150 .2724
No 2441 (79) 660 (21) 1287 (41) 1834 (59) 1293 (41) 1829 (59)
Yes 3379 (78) 969 (22) 1720 (39) 2675 (61) 1741 (40) 2663 (60)
(b)
Risk factors PPARD rs2016520 PPARG rs1801282
CC CT/TT P value Pro/Pro Pro/Ala or Ala/Ala P value
Age, mean(SD) 53.0 (15.4) 53.0 (15.5) .9640 52.9 (15.4) 53.2 (15.3) .4587
BMI, kg/m2, n (%) .9138 .1280
<25 2534 (64) 1389 (36) 3085 (79) 832 (21)
25–30 2190 (64) 1246 (36) 2668 (78) 757 (22)
>30 1136 (65) 609 (35) 1346 (77) 403 (23)
Cholesterol no Rx, mg/dL, n (%) .0161 .7401
≤200 2475 (66) 1290 (34) 2953 (78) 811 (22)
200–239 2011 (63) 1161 (37) 2467 (78) 705 (22)
≥240 1019 (63) 604 (37) 1261 (78) 354 (22)
Cholesterol with Rx, mg/dL, n (%) .3821 .6233
≤200 74 (67) 37 (33) 86 (80) 22 (20)
200–239 135 (69) 62 (31) 148 (76) 48 (24)
≥240 106 (63) 63 (37) 128 (76) 40 (24)6 PPAR Research
(b) Continued.
Risk factors PPARD rs2016520 PPARG rs1801282
CC CT/TT P value Pro/Pro Pro/Ala or Ala/Ala P value
Blood pressure, n (%) .8076 .2636
Normal 1441 (64) 812 (36) 1769 (79) 483 (21)
Prehypertensive 3578 (65) 1939 (35) 4312 (78) 1199 (22)
Hypertensive 842 (63) 491 (37) 1016 (77) 312 (23)
Combined outcomes
Diabetes, n (%) .6185 .1278
No 3747 (65) 2058 (35) 4517 (78) 1275 (22)
Yes 675 (64) 383 (36) 841 (80) 212 (20)
High cholesterol, n (%) .3178 .3691
No 2060 (64) 1175 (36) 2516 (78) 713 (22)
Yes 2263 (65) 1225 (35) 2732 (79) 740 (21)
High blood pressure, n (%) .9412 .8331
No 2006 (64) 1121 (36) 2462 (78) 676 (22)
Yes 2821 (64) 1564 (36) 3384 (78) 971 (22)
contrast, females were more likely to have cholesterol levels
greater than 200mg/dL, either with or without cholesterol
medication use, than males. There were no gender diﬀer-
ences in baseline age or PPAR SNP prevalence.
Table 2 shows the age-adjusted associations between the
PPARSNPsandcardiovascularriskfactorsexaminedatbase-
line and at follow up. After adjustment for age, BMI at base-
line was signiﬁcantly associated with the PPARG rs4684847
SNP such that individuals with at least one of the less com-
mon T alleles were signiﬁcantly more likely to have a higher
BMI than individuals carrying the CC genotype. Cholesterol
level (without medication use) at baseline was signiﬁcantly
associated with the PPARG rs1175543, the PPARG rs709158,
andthePPARDrs2016520SNPs.Speciﬁcally,individualscar-
rying the PPARG rs1175543 AA, the PPARG rs709158 AA,
or the PPARD rs2016520 CT or TT genotypes were signiﬁ-
cantlymorelikelytobecategorizedashavingbaselinecholes-
terol levels of 240mg/dL or greater compared to those with
the PPARG rs1175543 AG or GG, the PPARG rs709158 AG
or GG, or the PPARD rs2016520 CC genotypes, respectively.
Further, participants carrying the PPARG rs4684847 CT or
TTgenotypesweremorelikelytobecategorizedasbeingpre-
hypertensiveorhypertensiveatbaselinecomparedtopartici-
pants carrying the CC genotype. No statistically signiﬁcantly
associations were observed between any of the PPAR sNPs
and high blood pressure, high cholesterol, or diabetes diag-
noses over the entire followup period. To note, after adjust-
ment for multiple testing, none of the associations between
the SNPs and the cardiovascular risk factors were statistically
signiﬁcant.
There were no statistically signiﬁcant associations be-
tween the PPAR SNPs and cardiovascular deaths or events
(including nonfatal events combined and MI alone) (see
Table 3). A 40% reduction in the risk of premature cardio-
vascular death was observed for individuals with the PPARG
rs4684847 CT or TT genotype compared to the CC geno-
type; however, the conﬁdence interval was wide due to a
small number of deaths (see Table 4). There were no statis-
tically signiﬁcant associations for premature death (all cause
and cardiovascular-related) and PPARG rs709158, PPARG
rs1175543, PPARG Pro12Ala, and PPARD rs2016520.
4. DISCUSSION
In general, the ﬁndings from this prospective, community-
based cohort study indicate that the selected SNPs in PPAR
genes are not associated with overall and premature cardio-
vascular morbidity and mortality. Further, with a few excep-
tions, we found that the selected PPAR SNPs were not asso-
ciated with risk factors of cardiovascular disease. These ﬁnd-
ings were consistent among both men and women, among
those with a diagnosis of diabetes, and in strata deﬁned by
baseline BMI.
Data on PPAR polymorphisms and cardiovascular dis-
ease and cardiovascular disease risk factors are limited and
inconsistent.ThemoststudiedPPARpolymorphism,PPARG
Pro12Ala, has been shown to be associated with reduced
PPARG activity [14], and initial studies reported a lower
risk of type 2 diabetes associated with the Ala12 allele [14].
This association was observed in some [15–19], but not all
[20–23], subsequent studies. The lack of consistency also ex-
tends to studies examining the PPARG Pro12Ala polymor-
phism and cardiovascular disease events: one prospective co-
hort study examining the PPARG Pro12Ala polymorphism
andcardiovasculardiseasesuggestedadecreasedriskofCHD
among carriers of the Ala12 allele [8], while others have
shownnoassociation[9,10,24]oranincreaseinrisk[9,25].
Although our study was limited by the small number of car-
diovascular events, our results are consistent with those pre-
viousstudiesthathaveshownnoassociation.Thisﬁnding,as
wellasthedatashowingalackofassociationbetweenPPARG
Pro12Ala and cardiovascular risk factors, suggests that this
SNPisnotinvolvedinthedevelopmentofcardiovasculardis-
ease in this population.
While most of the analyses conducted resulted in null
ﬁndings, statistically signiﬁcant age-adjusted associationsL. Gallicchio et al. 7
Table 3: Age-adjusted hazard ratios (HR) and 95% conﬁdence intervals (95% CI) of all-cause and cardiovascular mortality and nonfatal
cardiovascular events for 5 PPAR polymorphisms. Person years: cumulative person years of follow up. RR (95% CI): relative risk using
poisson regression.
All-cause death CV-related death Nonfatal CV events Fatal and nonfatal CV events
SNPs Person years n HR (95% CI) n HR (95% CI) n RR (95% CI) RR (95% CI)
PPARG rs4684847
CC 92827 1705 1.00 (reference) 416 1.00 (reference) 2351 1.00 (reference) 1.00 (reference)
CT/TT 25880 474 0.95 (0.85–1.05) 114 0.90 (0.73–1.11) 679 1.00 (0.73–1.37) 0.88 (0.67–1.18)
PPARG rs709158
AA 47812 850 1.00 (reference) 205 1.00 (reference) 1202 1.00 (reference) 1.00 (reference)
AG/GG 71972 1328 0.99 (0.91–1.09) 324 1.02 (0.86–1.20) 1843 0.98 (0.75–1.28) 0.98 (0.77–1.24)
PPARG rs1175543
AA 48172 867 1.00 (reference) 213 1.00 (reference) 1183 1.00 (reference) 1.00 (reference)
AG/GG 71627 1331 1.0 (0.92–1.09) 316 0.99 (0.83–1.18) 1864 1.03 (0.79–1.34) 1.00 (0.79–1.28)
PPARD rs2016520
CC 77042 1386 1.00 (reference) 342 1.00 (reference) 2027 1.00 (reference) 1.00 (reference)
CT/TT 42593 766 1.03 (0.94–1.12) 178 1.02 (0.85–1.23) 1003 0.91 (0.69–1.19) 0.98 (0.76–1.26)
PPARG rs1801282
Pro/Pro 93254 1696 1.00 (reference) 408 1.00 (reference) 2350 1.00 (reference) 1.00 (reference)
Pro/Ala or Ala/Ala 26196 456 0.96 (0.86–1.06) 112 0.97 (0.79–1.20) 656 0.98 (0.71–1.35) 0.96 (0.72–1.28)
Table 4: Age-adjusted hazard ratios (HR) and 95% conﬁdence intervals (95% CI) of premature (age <65 years) all-cause and cardiovascular
mortality for 5 PPAR SNPs. Person years: cumulative person years of follow up.
All-cause death CV-related death
SNPs Person years n HR (95% CI) n HR (95% CI)
PPARG rs4684847
CC 43445 231 1.00 (reference) 27 1.00 (reference)
CT/TT 11743 58 1.05 (0.78–1.40) 4 0.60 (0.21–1.72)
PPARG rs709158
AA 23078 115 1.00 (reference) 13 1.00 (reference)
AG/GG 32822 175 1.05 (0.83–1.33) 18 0.95 (0.47–1.95)
PPARG rs1175543
AA 22875 115 1.00 (reference) 14 1.00 (reference)
AG/GG 32859 175 1.04 (0.82–1.32) 17 0.83 (0.41–1.68)
PPARD rs2016520
CC 36389 186 1.00 (reference) 21 1.00 (reference)
CT/TT 19940 99 0.98 (0.77–1.25) 9 0.79 (0.36–1.71)
PPARG rs1801282
Pro/Pro 44263 236 1.00 (reference) 25 1.00 (reference)
Pro/Ala or Ala/Ala 12247 50 0.90 (0.66–1.23) 5 0.79 (0.30–2.09)
were observed for PPARG rs4684847 with both baseline
BMI and blood pressure, and for PPARG rs709158, PPARG
rs1175543 and PPARD rs2016520 with baseline cholesterol
levels. These associations were not statistically signiﬁcant
when self-reported blood pressure or high cholesterol at any
time point over the study period were considered as out-
come variables. Further, the statistical signiﬁcance of the as-
sociations disappeared after correction for multiple testing.
However, this may be due to a lack of statistical power. To
our knowledge, these polymorphisms have not been exam-
ined in relation to cardiovascular disease or cardiovascu-
lar disease risk factors. Further, the functionalities of these
polymorphisms are unknown. Although located in intron
regions, these polymorphisms may aﬀect enzyme distribu-
tion or other physiological functions related to cardiovascu-
lar health. Alternatively, it may be that the associations ob-
served with these SNPs in this study are due to the polymor-
phismsbeinginlinkagedisequilibriumwithotherfunctional
polymorphisms in the respective regions.
Severallimitationsofthisstudymustbeconsideredwhen
interpreting the results. First, all of the followup data on car-
diovascular risk factors and events were based on self-report.
Because of this, there were some missing data for those
who did not complete any of the followup questionnaires.8 PPAR Research
Further, among those who did complete the questionnaires,
there is the possibility of misclassiﬁcation; this would likely
be nondiﬀerential, resulting in a dilution of the true risk es-
timate. However, in another investigation of this population,
self-report of incidence of MI was compared to data gath-
ered from on ongoing county-wide surveillance of MI events
documented by hospital review and the sensitivity and speci-
ﬁcity of reports were in excess of 94% (HY Huang, personal
communication). A second limitation is that because of the
racial homogeneity of the sample we were not able to explore
potential racial diﬀerences in the associations between the
PPAR polymorphisms and cardiovascular disease. In a previ-
ous publication [12], we did ﬁnd, however, racial diﬀerences
in the prevalence of the PPAR polymorphisms in this study
that are consistent with those published in the SNP500 and
dbSNP databases.
5. CONCLUSIONS
The results from this prospective, community-based cohort
study showed no association between the selected PPAR
polymorphisms andcardiovascularmorbidity andmortality.
Inaddition,ingeneral,nostatisticallysigniﬁcantassociations
were observed between the PPAR polymorphisms and car-
diovascular risk factors. Future studies should be conducted
to conﬁrm these ﬁndings and to explore the associations in
populations with greater racial and ethnic heterogeneity.
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